DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Idursulfase

Idursulfase

  • Ten Years of the Hunter Outcome Survey (HOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry Joseph Muenzer1, Simon A

    Ten Years of the Hunter Outcome Survey (HOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry Joseph Muenzer1, Simon A

  • Publications in Scientific Journals (Peer Reviewed) 1

    Publications in Scientific Journals (Peer Reviewed) 1

  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment

    Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment

  • Specialty Drug Benefit Document

    Specialty Drug Benefit Document

  • Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic

    Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic

  • September 2017 ~ Resource #330909

    September 2017 ~ Resource #330909

  • Understanding Elaprase® (Idursulfase) Therapy

    Understanding Elaprase® (Idursulfase) Therapy

  • Biologics and Biosimilars: Background and Key Issues

    Biologics and Biosimilars: Background and Key Issues

  • Translating Rare-Disease Therapies Into Improved Care for Patients and Families

    Translating Rare-Disease Therapies Into Improved Care for Patients and Families

  • Enzyme Replacement LSD Combined Policy

    Enzyme Replacement LSD Combined Policy

  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

  • Shire Collaboration Brings Validation to Armagen's Drug-Delivery Technology

    Shire Collaboration Brings Validation to Armagen's Drug-Delivery Technology

  • 1 Darbà Josep1, Ascanio Meritxell2 1 Universitat De Barcelona, Barcelona, Spain; 2 BCN Health Economics & Outcomes Research

    1 Darbà Josep1, Ascanio Meritxell2 1 Universitat De Barcelona, Barcelona, Spain; 2 BCN Health Economics & Outcomes Research

  • A GUIDE to ELAPRASE® REIMBURSEMENT Information for Healthcare Providers, Patients, and Families

    A GUIDE to ELAPRASE® REIMBURSEMENT Information for Healthcare Providers, Patients, and Families

  • Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials

    Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials

  • Evaluation of Impact of Anti-Idursulfase Antibodies During Long-Term Idursulfase Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients

    Evaluation of Impact of Anti-Idursulfase Antibodies During Long-Term Idursulfase Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients

  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text

    Active Moiety Name FDA Established Pharmacologic Class (EPC) Text

  • Lists of Medicinal Products for Rare Diseases in Europe*

    Lists of Medicinal Products for Rare Diseases in Europe*

Top View
  • Clinical Trials, Progression-Speed Differentiating Features, and Swiftness Rule of the Innovative Targets of First-In-Class Drugs
  • Specialty Drug List 10-24-11
  • May2013 CPG Updates
  • Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change
  • 1986 Senior Staff Fellow, Human Genetics Branch National Institute of Child Health and Human Developmental Bethesda, MD
  • Lysosomal Storage Disorders
  • Availability, Accessibility and Delivery to Patients of the 28 Orphan
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
  • CDER List of Licensed Biological Products With
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
  • NCL Red List at All NCL Trusts Except RNOH, Who Can Share Prescribing with a GP Within the Context of Their MDT OPAT Service
  • Medical Policy Statement
  • Idursulfase 1 .Pub
  • China Rare Disease Market: Large and Untapped Opportunity
  • For Peer Review Only - Page 1 of 59 BMJ Open
  • Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
  • Biochemical Genetics
  • An Overview of the Orphan Medicines Market in Turkey Güvenç Koçkaya, MD, Msc1,*, Albert I


© 2024 Docslib.org    Feedback